supra-pharmacologic dexamethasone sodium phosphate AVM0703

A supra-pharmacologic, high-volume formulation containing the sodium phosphate form of the corticosteroid dexamethasone, with potential antineoplastic and lymphoablative, and with anti-inflammatory and immunomodulating activities. Upon administration of supra-pharmacologic dexamethasone sodium phosphate AVM0703, dexamethasone targets and binds to the cytoplasmic glucocorticoid receptor (GR); then the receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins. More importantly, AVM0703 is able to supercharge and mobilize various lymphocytes and monocytes, such as natural killer T cells (NK/T), gamma delta T cells and dendritic cells (DCs). These immune cells, in turn, invade and destroy certain tumor cells. In addition, these immune cells that are induced by AVM0703 may also be able to kill viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By depleting monocytes, AVM0703 may also reduce cytokine-release syndrome (CRS). AVM0703 also lympho-ablates both T and B lymphocytes for 'immune reset' via receptor mediated induction of caspase dependent apoptosis. This specific dexamethasone formulation contains about twenty-five times the dose of other dexamethasone formulations. AVM0703 does not have an effect on red blood cells (RBCs), platelets, and hematopoietic stem cells (HSCs).